首页> 外文期刊>Haemophilia: the official journal of the World Federation of Hemophilia >Population pharmacokinetic modelling of factor IX activity after administration of recombinant factor IX in patients with haemophilia B
【24h】

Population pharmacokinetic modelling of factor IX activity after administration of recombinant factor IX in patients with haemophilia B

机译:乙型血友病患者给予重组IX因子后IX因子活性的群体药代动力学模型

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: The aim is to develop a pharmacokinetic model for factor IX activity (FIX) after BeneFIX (nonacog alfa, rFIX) administration and assess potential covariates using all available clinical data collected during development. Methods: The data set for model development combined observations from eight studies. Postdose FIX observations were adjusted by subtracting predose FIX if these were above the lower limit of quantification (BLQ) and all BLQ observations were removed. A population pharmacokinetic model was then developed with 4936 observations from 201 patients. Two additional studies (385 observations from 72 patients) became available and were used to evaluate the model. Results: A two-compartment model, parameterized for clearance (CL), volume of distribution of the central (V1) and peripheral (V2) compartments, and intercompartmental clearance (Q), with an effect of weight on all parameters was the final model. Weight was incorporated as a power function with exponent estimates close to conventional allometric scaling. Including interoccasion variability (IOV) on CL and V1 showed decreases in the objective function. Investigations of a full block omega matrix lead to the retention of a correlation between V2 and Q. Age was not a significant covariate with weight already included in the model. Observations in the studies used for evaluation were found to be higher than simulated values immediately after dosing, as well as a week after dosing. The differences may be due perhaps to differences in the patients enrolled in the evaluation studies (all were adults) as well as the sample collection time after dosing (longer after dosing in the evaluation studies). Conclusions: FIX is appropriately modelled as a two-compartment model after rFIX administration. When weight is included, no additional effect of age is observed. Longer times of observation after dosing may be helpful in refining the model.
机译:目的:目的是在给予BeneFIX(nonacog alfa,rFIX)后建立IX因子活性(FIX)的药代动力学模型,并使用在开发过程中收集的所有可用临床数据评估潜在的协变量。方法:用于模型开发的数据集结合了来自八项研究的观察结果。如果剂量后FIX观察值高于定量下限(BLQ),则通过减去剂量前FIX来调整剂量后FIX观察值,并删除所有BLQ观察值。然后用201名患者的4936项观察结果开发了群体药代动力学模型。另外还有两项研究(来自72位患者的385项观察结果)可用于评估模型。结果:最终参数模型是一个两室模型,其参数设置为间隙(CL),中央(V1)和外围(V2)室的分布体积以及室间间隙(Q),并且重量对所有参数都有影响。权重作为幂函数并入,指数估计接近传统的异度缩放比例。包括CL和V1的场合间变异(IOV)表明目标函数减小。对全块欧米茄矩阵的研究导致保留了V2和Q之间的相关性。年龄与模型中已包含的体重无关,不是显着的协变量。发现用于评估的研究中观察到的结果在给药后以及给药后一周都高于模拟值。差异可能是由于参与评估研究的患者(均是成年人)以及给药后样品收集时间的差异(评估研究中给药后较长)造成的。结论:在rFIX管理后,FIX被适当地建模为两部分模型。当包括体重时,没有观察到年龄的其他影响。给药后较长时间的观察可能有助于改善模型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号